Simulation-Based Patient Education to Address Radiotherapy-Related Anxiety in Cancer Patients (ARAISE) (ARAISE)
Addressing Radiotherapy Anxiety Through Immersive Simulation and Education: Effects of a Simulation-Based Patient Education Intervention on Psychosocial Burden in Cancer Patients Receiving Radiotherapy (ARAISE)
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Rami El Shafie, Prof. Dr. med
- Número de teléfono: +49 551 3964501
- Correo electrónico: rami.elshafie@med.uni-goettingen.de
Copia de seguridad de contactos de estudio
- Nombre: Stephan-Peter Landgraff, M.Ed.
- Número de teléfono: +49 30 76 68 37 5 600
- Correo electrónico: stephan.landgraff@medicalschool-berlin.de
Ubicaciones de estudio
-
-
Lower Saxony
-
Göttingen, Lower Saxony, Alemania, 37075
- Department of Radiotherapy and Radiation Oncology, University Medical Center Goettingen
-
Contacto:
- Stephan-Peter Landgraff, M.Ed.
- Número de teléfono: +49 5513964501
- Correo electrónico: stephan.landgraff@medicalschool-berlin.de
-
Contacto:
- Rami El Shafie, Prof. Dr. med.
- Número de teléfono: +49 5513964501
- Correo electrónico: rami.elshafie@med.uni-goettingen.de
-
Investigador principal:
- Rami El Shafie, Prof. Dr. med.
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Age 18 years or older
- Histologically or cytologically confirmed malignant tumor disease
- Stage I - III (UICC TNM classification)
- ECOG performance status ≤ 2
- Curative-intent external beam radiotherapy regimen with at least 5 fractions
- First course of radiotherapy
- Able to independently operate the electronic data collection instrument
- Written informed consent after study information
- Sufficient German language proficiency to read and complete the study questionnaires independently and without translation assistance
Exclusion Criteria:
- Lack of capacity to provide informed consent
- Pregnancy or breastfeeding
- Stereotactic radiotherapy
- Emergency treatment indication
- Acute suicidality, acute psychosis, or other acute psychiatric disorder
- Initiation of or dose change in psychotropic medication within 4 weeks before baseline (T0)
- Cognitive impairment that precludes independent completion of the questionnaires
- Visual or auditory impairment that prevents perception of the on-screen or audio content despite available aids
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Sin intervención: Standard Patient Education
Participants receive standard patient education before radiotherapy according to routine clinical practice.
Standard patient education comprises the physician consultation covering the indication and aim of radiotherapy, treatment planning and delivery, possible acute and late side effects, and organizational aspects of care.
No simulation-based education session is provided.
Prescribed oncological treatment and routine radiotherapy care are not altered.
|
|
|
Experimental: Simulation-Based Patient Education
Participants receive standard patient education as in the control arm and, in addition, a single structured simulation-based patient education session after the planning CT and before the first radiotherapy fraction.
|
A single, standardized, simulation-based patient education session lasting 15 to 20 minutes, conducted in addition to the standard education session that takes place after the planning CT scan and before the first radiation therapy fraction.
This session uses the immersive radiation therapy simulation software VERT 9.0 to visualize the treatment room, the linear accelerator, and the treatment process.
In addition to illustrating the treatment process, targeted information is provided to address treatment-specific fears identified as priorities in the Delphi consensus.
The session is conducted by the principal investigator following a standardized procedure to ensure comparability among participants.
The prescribed oncological treatment and routine radiation therapy remain unchanged.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
State anxiety at the first radiotherapy fraction (STAI-G Form X1)
Periodo de tiempo: First radiotherapy fraction (T2), approximately 2 weeks after randomization
|
State anxiety at the first radiotherapy fraction (T2), measured with the state scale (Form X1) of the German version of the State-Trait Anxiety Inventory (STAI-G).
The sum score comprises 20 items and ranges from 20 to 80, with higher scores indicating greater state anxiety.
The adjusted between-group difference in means at T2 is analyzed by analysis of covariance with the baseline state anxiety score at T0 as a continuous covariate and dichotomized trait anxiety at T0 as a factor.
The effect measure is the adjusted mean difference with a 95% confidence interval.
|
First radiotherapy fraction (T2), approximately 2 weeks after randomization
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
State anxiety after the planning CT or education session (STAI-G Form X1)
Periodo de tiempo: T1, immediately after the planning CT or after the education session, approximately 1 week after randomization
|
State anxiety at T1, measured with the state scale (Form X1) of the German version of the State-Trait Anxiety Inventory (STAI-G).
Scores range from 20 to 80, with higher scores indicating greater state anxiety.
Analyzed by analysis of covariance with the baseline state anxiety score at T0 as a continuous covariate and dichotomized trait anxiety at T0 as a factor.
|
T1, immediately after the planning CT or after the education session, approximately 1 week after randomization
|
|
State anxiety at the fifth radiotherapy fraction (STAI-G Form X1)
Periodo de tiempo: Fifth radiotherapy fraction (T3), approximately 3 weeks after randomization
|
State anxiety at T3, measured with the state scale (Form X1) of the German version of the State-Trait Anxiety Inventory (STAI-G).
Scores range from 20 to 80, with higher scores indicating greater state anxiety.
Analyzed by analysis of covariance with the baseline state anxiety score at T0 as a continuous covariate and dichotomized trait anxiety at T0 as a factor.
|
Fifth radiotherapy fraction (T3), approximately 3 weeks after randomization
|
|
Health-related quality of life: Global Health Status/Quality of Life (EORTC QLQ-C30)
Periodo de tiempo: Fifth radiotherapy fraction (T3), approximately 3 weeks after randomization
|
Health-related quality of life at T3, measured with the EORTC QLQ-C30 and linearly transformed to a score from 0 to 100, with higher scores indicating a greater global health status and quality of life.
Analyzed by analysis of covariance with group as a factor, the T0 Global Health Status/Quality of Life score as a continuous covariate, and dichotomized trait anxiety at T0 as a factor.
Functioning and symptom scales are reported descriptively only.
|
Fifth radiotherapy fraction (T3), approximately 3 weeks after randomization
|
|
Perceived amount of information received: "Information about the treatment" scale (EORTC QLQ-INFO25)
Periodo de tiempo: T1, immediately after the planning CT or after the education session, approximately 1 week after randomization
|
Perceived amount of information received at T1, measured with the multi-item scale "Information about the treatment" (items 38 to 43) of the EORTC QLQ-INFO25 and linearly transformed to a score from 0 to 100, with higher scores indicating a greater perceived amount of information.
Groups are compared in a linear model with group as a factor and dichotomized trait anxiety at T0 as the only adjustment variable.
The remaining multi-item scales, single items, the total score, and the assessment at T2 are reported descriptively.
|
T1, immediately after the planning CT or after the education session, approximately 1 week after randomization
|
|
Feasibility of the simulation-based patient education intervention
Periodo de tiempo: From enrollment to the fifth radiotherapy fraction (T3), approximately 3 weeks per participant
|
Composite descriptive endpoint with target values defined a priori: recruitment rate of at least 50%, retention rate of at least 80% at T3, protocol adherence of at least 90%, data completeness of at least 85% from T0 to T3, and tolerability defined as discontinuation due to intervention-associated distress reactions in no more than 10% of participants.
All rates are reported with two-sided 95% confidence intervals.
No formal hypothesis testing is performed.
|
From enrollment to the fifth radiotherapy fraction (T3), approximately 3 weeks per participant
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Moderation of the intervention effect on state anxiety at T2 by trait anxiety
Periodo de tiempo: First radiotherapy fraction (T2), approximately 2 weeks after randomization
|
Dispositional trait anxiety is measured once at baseline (T0) with the trait scale (Form X2) of the German version of the State-Trait Anxiety Inventory (STAI-G) and dichotomized at a threshold of 40 points or higher.
The group-by-trait-anxiety interaction term is tested in the analysis of covariance model of the primary endpoint (state anxiety at T2). Dichotomized trait anxiety additionally serves as a stratification factor for randomization and as a prognostic factor in all analyses of state anxiety.
This analysis is not independently powered and is interpreted as hypothesis-generating.
|
First radiotherapy fraction (T2), approximately 2 weeks after randomization
|
|
Effect modification of the primary endpoint by prespecified participant and treatment characteristics
Periodo de tiempo: First radiotherapy fraction (T2), approximately 2 weeks after randomization
|
Effect modification of state anxiety at T2 by irradiation site (central nervous system, head and neck, breast, thorax, abdomen, pelvis), sex, educational level, and concomitant systemic therapy, assessed via the respective interaction terms with treatment allocation in the model of the primary endpoint.
These analyses are not independently powered and are interpreted as hypothesis-generating.
|
First radiotherapy fraction (T2), approximately 2 weeks after randomization
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Rami El Shafie, Prof. Dr. med., Department of Radiotherapy and Radiation Oncology, University Medical Center Goettingen (UMCG)
- Director de estudio: Stephan-Peter Landgraff, M.Ed., Faculty of Health Sciences, Medical School Berlin (MSB)
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- ARAISE-RT-UMG-2026
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .